[18F]RCCB6 PET/CT诊断透明细胞肾细胞癌的前瞻性对比研究
这项单中心前瞻性II期试验评估了靶向CD70的[18F]RCCB6 PET/CT在透明细胞肾细胞癌转移检测中的价值,并与[18F]FDG PET/CT及常规影像进行对比。在可评估的1221个肾外病灶中,[18F]RCCB6 PET/CT灵敏度达94.2%,在头对头比较中显著优于[18F]FDG PET/CT和常规影像,且58.7%患者的临床管理因此改变。
要点
- [18F]RCCB6 PET/CT检测ccRCC转移灵敏度94.2%、PPV 98.3%。
- 头对头比较中灵敏度90.5% vs [18F]FDG 41.1%(P<0.001)。
- 58.7%患者因该影像改变临床管理。
核心结论
- [18F]RCCB6 PET/CT是诊断ccRCC转移的高灵敏度影像手段,可影响临床决策。
研究设计与样本
- 单中心前瞻性II期试验,筛选291例后150例经组织学确诊或疑似肾癌患者接受成像。
主要发现
- 在1221个可评估肾外病灶中,[18F]RCCB6 PET/CT灵敏度94.2%、特异度80%、准确率93.1%、阳性预测值98.3%。
- 99例683个病灶头对头比较中,[18F]RCCB6灵敏度90.5% vs [18F]FDG 41.1%,特异度81.4% vs 24.3%(均P<0.001)。
- 748个病灶与常规影像比较,[18F]RCCB6灵敏度90.8% vs 75.1%,特异度81.6% vs 56.6%。
- [18F]RCCB6最大标准化摄取值与CD70表达强相关(r=0.843;P<0.001)。
- 影像发现使58.7%患者的临床管理发生改变。
临床怎么用
- 对疑似转移性ccRCC,[18F]RCCB6 PET/CT可提供高灵敏度分期信息并辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This single-center prospective phase II trial evaluated [18F]RCCB6 (renal cell carcinoma B6) positron emission tomography (PET)/computed tomography (CT), a cluster of differentiation 70 (CD70)-targeting radiotracer, for detecting metastases in clear-cell renal cell carcinoma (ccRCC). After screening 291 patients, 150 patients with histologically confirmed ccRCC or suspected kidney cancer underwent imaging. Among 1,221 assessable extrarenal lesions, [18F]RCCB6 PET/CT achieved 94.2% sensitivity, 80% specificity, 93.1% accuracy, and 98.3% positive predictive value. In a head-to-head comparison of 99 patients with 683 lesions, [18F]RCCB6 significantly outperformed 2-deoxy-2-[fluorine-18]fluoro-D-glucose ([18F]FDG) PET/CT, with higher diagnostic sensitivity (90.5% vs. 41.1%) and specificity (81.4% vs. 24.3%; both P < 0.001). Compared with conventional imaging across 748 lesions, [18F]RCCB6 PET/CT also demonstrated superior sensitivity (90.8% vs. 75.1%) and specificity (81.6% vs. 56.6%). [18F]RCCB6 uptake (maximum standardized uptake value) strongly correlated with CD70 expression (r = 0.843; P < 0.001). Moreover, the imaging findings changed clinical management in 58.7% of patients. [18F]RCCB6 PET/CT is a highly sensitive imaging modality for diagnosing ccRCC metastases and informing clinical decision-making. SIGNIFICANCE: This phase II trial demonstrates that [18F]RCCB6 PET/CT significantly outperforms conventional imaging and [18F]FDG PET/CT in detecting metastatic ccRCC, with 94.2% sensitivity and strong correlation with CD70 expression, altering clinical management in 58.7% of patients.
引用
- Wu Q, An S, Gelardi F, et al. [18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging. Cancer Discov. 2026. PMID: 42112793. doi:10.1158/2159-8290.CD-26-0016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。